PTC Therapeutics

Yahoo Finance • 22 days ago

Sector Update: Healthcare Stocks Lower Late Afternoon

Healthcare stocks declined late Friday afternoon, with the NYSE Healthcare Index and the State Stree PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 24 days ago

Global RNA Targeting Small Molecule Drug Discovery Market Size/Share Worth USD 17.6 Billion by 2035 at a 22.1% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, SWOT Analysis)

Custom Market Insights [220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global RNA Targeting Small Molecule Drug Discovery Market size & share revenue was valued at... Full story

Yahoo Finance • 28 days ago

PTC Therapeutics (PTCT) Reports Positive Huntington’s Disease Trial Results

PTC Therapeutics, Inc. (NASDAQ:PTCT) ranks among the most profitable biotech stocks to buy now. On April 28, PTC Therapeutics, Inc. (NASDAQ:PTCT) announced positive outcomes from a 24-month interim assessment of its PIVOT-HD extension tria... Full story

Yahoo Finance • 30 days ago

PTC Therapeutics (PTCT) Is Down 5.1% After New Votoplam Huntington’s Data And Novartis Milestone

Earlier this week, PTC Therapeutics reported positive 24‑month interim data from the PIVOT-HD extension study, showing dose-dependent slowing of Huntington’s disease progression with votoplam and a favorable long-term safety and biomarker... Full story

Yahoo Finance • last month

PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam

- Dose-dependent benefit on cUHDRS in Stage 2 participants compared to matched natural history cohort, with 52% slowing at 10 mg dose - - Continued evidence of favorable safety profile - - Novartis initiated global Phase 3 INVEST-HD stud... Full story

Yahoo Finance • last month

PTC Therapeutics to Report Results from PIVOT-HD Long Term Extension Study

WARREN, N.J., April 28, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a webcast conference call today, April 28 at 4:30 p.m. ET to share results from the 24-month interim analysis of the PIVOT-HD long-term extension... Full story

Yahoo Finance • last month

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WARREN, N.J., April 17, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 13, 2026, the company approved non-statutory stock options to purchase an aggregate of 1,155 shares of its common stock and 92... Full story

Yahoo Finance • 2 months ago

Netflix initiated, Instacart upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Jefferies upgraded Instacart (CART) to... Full story

Yahoo Finance • 2 months ago

This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story

Key Points RTW Investments established a new position in Apellis Pharmaceuticals, adding 7,666,764 shares during the fourth quarter. The quarter-end value of the Apellis stake was $192.59 million, reflecting the new position added by RTW... Full story

Yahoo Finance • 2 months ago

This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch

RTW Investments disclosed a significant buy of Cogent Biosciences(NASDAQ:COGT) in its February 17, 2026, SEC filing, adding 4,124,755 shares in a trade estimated at $115.95 million based on quarterly average pricing. What happened Accord... Full story

Yahoo Finance • 3 months ago

Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing

Palo Alto Investors LP reported a buy of 41,303 shares of PTC Therapeutics(NASDAQ:PTCT) in its February 17, 2026, SEC filing, with an estimated transaction value of $3.00 million based on quarterly average pricing. What Happened Accordin... Full story

Yahoo Finance • 3 months ago

Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing

Key Points 209,523-share increase in Dyne Therapeutics; estimated transaction value $3.97 million (based on quarterly average pricing) Quarter-end position in Dyne Therapeutics rose $12.82 million in value, reflecting both trading and sto... Full story

Yahoo Finance • 3 months ago

Oversold Conditions For PTC Therapeutics (PTCT)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the R... Full story

Yahoo Finance • 3 months ago

PTC Therapeutics stock down over 2% on worse-than-expected Q4 results, guidance

Investing.com -- PTC Therapeutics (NASDAQ: PTCT) reported fourth-quarter results that missed Wall Street expectations on both earnings and revenue, even as management pointed to strong momentum from the recent launch of Sephience™. Shares... Full story

Yahoo Finance • 4 months ago

PTC Therapeutics drops as it pulls Translarna NDA resubmission

[US Food and Drug Administration (FDA)] * PTC Therapeutics (PTCT [https://seekingalpha.com/symbol/PTCT]) is down ~5% in after-hours trading Thursday after announcing it has withdrawn its NDA resubmission of Translarna (ataluren) for non... Full story

Yahoo Finance • 5 months ago

Royalty Pharma buys remaining royalty interest in Roche drug Evrysdi

[Roll of dollars with sign royalties and keyboard.] designer491 * Royalty Pharma (RPRX [https://seekingalpha.com/symbol/RPRX]) has acquired from PTC Therapeutics (PTCT [https://seekingalpha.com/symbol/PTCT]) its remaining royalty intere... Full story

Yahoo Finance • 5 months ago

PTC Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

WARREN, N.J., Dec. 18, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that CEO Matthew B. Klein, M.D., will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 12, 2026, at 9 a.m. PST/12... Full story

Yahoo Finance • 6 months ago

PTC Therapeutics Investors Focus on Sephience Uptake, Huntington's Updates, RBC Says

PTC Therapeutics (PTCT) investors are expected to remain focused on the Sephience rollout for phenyl PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 6 months ago

Principal Spectrum Preferred Secs Active ETF declares monthly distribution of $0.0827

* Principal Spectrum Preferred Secs Active ETF (PREF [https://seekingalpha.com/symbol/PREF]) - $0.0827 [https://www.principalam.com/fund/pref]. * Payable Dec 03, 2025; for shareholders of record Dec 01, 2025; ex-div Dec 01, 2025. MORE... Full story

Yahoo Finance • 6 months ago

Principal Investment Grade Corporate Active ETF declares monthly distribution of $0.0792

* Principal Investment Grade Corporate Active ETF (IG [https://seekingalpha.com/symbol/IG]) - $0.0792 [https://www.principalam.com/us/fund/ig]. * Payable Dec 03, 2025; for shareholders of record Dec 01, 2025; ex-div Dec 01, 2025. MORE... Full story